Company news

Immunovant, Inc. (NASDAQ:IMVT) news

Immunovant, Inc. news releases on 6ix. Latest, Sep 23, 2026: Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus…

Immunovant, Inc. (NASDAQ:IMVT) news

Press releases & updates

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Immunovant Announces $450 Million Private Placement

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Ankyra Announces Appointment of Dr. Julia Butchko and Ms. Tara Withington to the Board of Directors

Roivant Provides Update on Graves’ Disease Development Program

Immunovant Provides Update on Graves’ Disease Development Program

Immunovant to Host Graves’ Disease Program Update on September 9, 2024

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2024

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Immunovant Awarded U.S. Patent for IMVT-1402

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Immunovant to Present at Upcoming Investor Conferences

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Immunovant Announces Pricing of $450 Million Common Stock Financing

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Immunovant to Present at Roivant Investor Day on September 28th

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Immunovant Announces Two New Development Programs for Batoclimab